Winst gevend schreef op 21 september 2025 12:32:
.
.
Sep 19, 2025 7:00am EDT
Head of the HAE clinic at Amsterdam UMC, University of Amsterdam, Netherlands
and principal investigator for the KONFIDENT phase 3 trial,
“With today’s approvals, this innovation can now be brought into clinical practice,
empowering patients and clinicians across Europe and Switzerland
with the first oral on-demand treatment for HAE.
First European launch of EKTERLY expected in Germany Q4 2025
EKTERLY now approved in the US, EU, UK and Switzerland,
with additional regulatory applications under review in key global markets.
www.nasdaq.com/press-release/kalvista...